Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Down 40.7% in November

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) saw a large decline in short interest in November. As of November 15th, there was short interest totalling 1,600 shares, a decline of 40.7% from the October 31st total of 2,700 shares. Based on an average daily trading volume, of 11,000 shares, the short-interest ratio is presently 0.1 days.

Enzon Pharmaceuticals Price Performance

Shares of ENZN traded down $0.01 during midday trading on Thursday, reaching $0.07. The stock had a trading volume of 28,744 shares, compared to its average volume of 24,139. Enzon Pharmaceuticals has a 52 week low of $0.06 and a 52 week high of $0.24. The firm’s 50 day moving average price is $0.10 and its 200-day moving average price is $0.13. The company has a market capitalization of $5.34 million, a P/E ratio of 7.20 and a beta of 0.53.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.